To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

Clinical trial NCT05388695 · RECRUITING

Trial details

NCT number: NCT05388695
Sponsor: Hebei Senlang Biotechnology Inc., Ltd.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

19 and 22+ B Cell Hematologic Tumors 19 and 20+ B Cell Hematologic Tumors

Start date: 2022-04-08
Primary completion: 2027-03-30
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.